Status: Recruiting
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB). A separate exploratory, open-label, single-dose cohort (Part C) will evaluate pegylated interferon alfa-2a in HVs for translational benchmarking against IB-001.
Participants needed: 88
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: IntegerBioUpdated: Sep 28, 2026Locations: 5
Eligibility criteria
Able and willing to provide written informed consent. [+3]
Major surgery requiring general anesthesia within 12 weeks prior to Screening or... [+56]